Year None2021202020192018201720162015201420132012 07.29.2020 Iveric Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 07.16.2020 Iveric Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors 06.30.2020 Iveric Bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration 06.22.2020 Iveric Bio Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds 06.18.2020 Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants 06.17.2020 Iveric Bio Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement 06.15.2020 Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial 06.14.2020 Iveric Bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 06.02.2020 Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 05.27.2020 Iveric Bio to Present at the Jefferies 2020 Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »